Deal for Kelonia Therapeutics could come as soon as Monday.

After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a path forward ...

A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing ...

Vertex Pharmaceuticals has given Mirum Pharmaceuticals the blueprint for success in rare diseases.

Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs ...

ALBANY, NY (NEWS10) – From the Capital of France to the Capital of New York — a cutting-edge biotech firm that uses AI to ...

The high-profile obesity drug developer priced the biotech sector’s biggest offering in years and will use the proceeds to ...

Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech ...

TheFly reported on April 7 that H.C. Wainwright reduced its price target on CVKD from $32 to $13 while maintaining a Buy ...

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...